To explore the potential downstream targets of JAK/STAT6-mediated MET, we examined the expression of GATA3 in cancer cells because GATA3 is a transcription factor that inhibits EMT and is expressed in early-stage well-differentiated cancers but decreases in advanced invasive cancers27–29, and STAT6 has been shown to activate GATA3 during T cell differentiation30,31. The gene discussed is GATA3; the disease is cancer.